Nutriband Inc
NTRB7.110USD
-0.280-3.79%
시장 운영 시간 （ET）시세는 15분 지연됩니다
78.74M시가총액
손실P/E TTM
자세한 내용은 Nutriband Inc 회사
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
회사 정보
종목 코드 NTRB
회사 이름Nutriband Inc
상장일Jun 20, 2017
CEOMr. Gareth Sheridan
직원 수- -
유형Ordinary Share
회계 연도 종료Jun 20
주소121 S Orange Ave Ste 1500
도시ORLANDO
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호32801-3241
전화14073776695
웹사이트https://nutriband.com/
종목 코드 NTRB
상장일Jun 20, 2017
CEOMr. Gareth Sheridan
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Gareth Sheridan
Mr. Gareth Sheridan
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
1.76M
--
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Secretary
Chairman of the Board, President, Secretary
820.42K
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
17.21K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
1.17K
--
Mr. Sergei Glinka
Mr. Sergei Glinka
Independent Director
Independent Director
--
--
Prof. Dr. Stefani C. Mancas
Prof. Dr. Stefani C. Mancas
Independent Director
Independent Director
--
--
Dr. Alan Smith, Ph.D.
Dr. Alan Smith, Ph.D.
Chief Operating Officer, President of 4P Therapeutics
Chief Operating Officer, President of 4P Therapeutics
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Gareth Sheridan
Mr. Gareth Sheridan
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
1.76M
--
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Secretary
Chairman of the Board, President, Secretary
820.42K
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
17.21K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
수익 분석
통화: USD마지막 업데이트: Sun, Jul 6
통화: USD마지막 업데이트: Sun, Jul 6
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
Sale of goods
667.43K
0.00%
Services
0.00
0.00%
지역별USD
이름
수익
비율
United States
667.43K
100.00%
Non-United States
0.00
0.00%
사업별
지역별
사업별USD
이름
수익
비율
Sale of goods
667.43K
0.00%
Services
0.00
0.00%
주식 보유 통계
마지막 업데이트: Sun, Jul 20
마지막 업데이트: Sun, Jul 20
주주
주주 유형
주주
주주
비율
Botgros (Vitalie)
27.68%
TII Jet Services, LDA
16.21%
Sheridan (Gareth)
15.79%
Glinka (Serguei)
7.40%
Melnik (Serguei)
7.36%
Other
25.57%
주주
주주
비율
Botgros (Vitalie)
27.68%
TII Jet Services, LDA
16.21%
Sheridan (Gareth)
15.79%
Glinka (Serguei)
7.40%
Melnik (Serguei)
7.36%
Other
25.57%
주주 유형
주주
비율
Individual Investor
60.16%
Corporation
16.21%
Investment Advisor
2.09%
Investment Advisor/Hedge Fund
0.83%
Research Firm
0.12%
Other
20.59%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
44
8.86M
79.41%
+467.78K
2025Q1
43
8.13M
73.14%
+1.78M
2024Q4
40
8.04M
72.39%
+1.68M
2024Q3
40
8.08M
72.79%
+1.82M
2024Q2
38
5.19M
52.25%
+2.18M
2024Q1
34
4.36M
55.65%
+1.38M
2023Q4
30
4.30M
54.90%
+1.31M
2023Q3
29
2.96M
37.78%
-39.44K
2023Q2
28
2.95M
37.71%
-29.57K
2023Q1
28
2.96M
37.92%
-64.00
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Botgros (Vitalie)
3.09M
27.68%
+716.50K
+30.22%
Apr 25, 2025
TII Jet Services, LDA
1.81M
16.21%
+485.05K
+36.66%
Sep 01, 2024
Sheridan (Gareth)
1.76M
15.79%
-103.00
-0.01%
Apr 25, 2025
Glinka (Serguei)
825.00K
7.4%
--
--
Apr 25, 2025
Melnik (Serguei)
820.42K
7.36%
--
--
Apr 25, 2025
The Vanguard Group, Inc.
199.03K
1.78%
+74.44K
+59.75%
Mar 31, 2025
Goodman (Gerald)
86.33K
0.77%
--
--
Apr 25, 2025
Geode Capital Management, L.L.C.
63.55K
0.57%
+1.11K
+1.79%
Mar 31, 2025
Smith (Allan)
41.91K
0.38%
-6.99K
-14.29%
Apr 25, 2025
Patrick (Jeff)
36.61K
0.33%
--
--
Apr 25, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Jul 29, 2022
Split
6>7
날짜
유형
비율
Jul 29, 2022
Split
6>7
